Rednex Pharmaceuticals IPO Details

Incorporated in 2020, Rednex Pharmaceuticals is a pharmaceutical manufacturing company, producing a wide range of medicines used across various therapeutic areas such as antibacterial, antifungal, antimalarial, pain relief, antacid, antiallergy, and more. The company also manufactures medicines for other companies under loan license and contract manufacturing arrangements.

Its manufacturing facility is located in Bavla, Ahmedabad, covering 9,212.63 sq. meters, and includes two separate manufacturing units:

1. General Pharma Plant– Produces common formulations like tablets, capsules, syrups, creams, gels, ointments, and lotions.
2. Beta Lactam Plant– Specially designed to manufacture antibiotics such as Cefixime, Amoxicillin, Cefuroxime, and Cephalexin, in tablets, capsules, and dry syrup forms. This unit operates independently to prevent contamination and meet international quality standards.

The manufacturing facility is well equipped with modern automated machinery, in-house laboratories, and storage facilities for raw materials and finished goods. It also hold certifications such as FDCA License, WHO Certificate, ISO 9001:2015 (Quality Management), and ISO 14001:2015 (Environmental Management).

The company also work with third-party companies under loan license arrangements, allowing them to market products under their own brand names.

The company sells products in both the domestic and international markets. Currently, it export through local merchant exporters to several countries including Angola, Cameroon, Congo, Fiji, Iraq, Liberia, Nigeria, UAE, Zambia, and others.

As on June 30, 2025, the company had 146 permanent employees.